Bausch Health CFO awarded RSUs, shares withheld

Bausch Health Companies Inc. EVP and CFO Jean-Jacques Charhon reported equity compensation and related tax withholding in this insider filing.

Rhea-AI Filing Summary

Bausch Health Companies Inc. EVP and CFO Jean-Jacques Charhon reported equity compensation and related tax withholding in this insider filing. On February 25, 2026, he acquired 276,055 restricted share units (RSUs) for no cash consideration. These RSUs vest one-third on each of the first three anniversaries of the grant date, and vested RSUs are settled in Bausch Health common shares.

On February 26, 2026, 35,977 common shares were disposed of at $6.04 per share to satisfy tax withholding obligations upon RSU vesting, rather than as an open-market sale. After these transactions, Charhon directly held 755,538 common shares of Bausch Health.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Charhon Jean-Jacques

Role EVP, CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares, No Par Value	35,977	$6.04	$217K
Grant/Award	Common Shares, No Par Value	276,055	$0.00	$0.00

Holdings After Transaction: Common Shares, No Par Value — 755,538 shares (Direct)

Footnotes (2)

1. F1. Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc.
2. F2. This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Bausch Health (BHC) CFO Jean-Jacques Charhon report?

Jean-Jacques Charhon reported an RSU grant and related tax withholding. He received 276,055 restricted share units, then 35,977 common shares were withheld at $6.04 per share to cover tax obligations arising from RSU vesting, rather than executed as an open-market sale.

How many RSUs were granted to Bausch Health (BHC) CFO and on what terms?

The CFO received 276,055 restricted share units for no cash cost. These RSUs vest in three equal installments on each of the first three anniversaries of the February 25, 2026 grant date, and each vested unit will be settled in Bausch Health common shares.

What was the purpose of the 35,977 Bausch Health (BHC) shares disposed of by the CFO?

The 35,977 common shares were withheld to satisfy tax withholding obligations from RSU vesting. They were recorded at $6.04 per share and represent a tax-withholding disposition, not an open-market sale, helping cover statutory taxes due on the equity compensation event.

What is Bausch Health (BHC) CFO Jean-Jacques Charhon’s share ownership after these Form 4 transactions?

After the reported RSU grant and tax-withholding disposition, Jean-Jacques Charhon directly owns 755,538 Bausch Health common shares. This figure reflects his post-transaction holdings following the 276,055 RSU award and the withholding of 35,977 shares to meet associated tax obligations.

Were the Bausch Health (BHC) CFO’s reported transactions open-market buys or sells?

The transactions were equity compensation-related, not open-market trades. One entry is a grant of 276,055 restricted share units at zero price, and the other is a disposition of 35,977 shares withheld to cover tax obligations on RSU vesting, rather than discretionary selling.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 05:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Charhon Jean-Jacques

(Last) (First) (Middle)

400 SOMERSET CORPORATE BLVD.

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bausch Health Companies Inc. [ BHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, No Par Value	02/25/2026		A		276,055(1)	A	$0	791,515	D
Common Shares, No Par Value	02/26/2026		F		35,977(2)	D	$6.04	755,538	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc.

2. This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

	/s/ Brianna M. Dorsi attorney-in-fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.